Sienna Biopharmaceuticals, Inc. announced the promotion of Alexander Azoy to Chief Financial Officer (CFO). Mr. Azoy, who has served as Sienna's Corporate Controller since December 2017, will succeed John W. Smither, who has resigned for personal reasons, effective April 1, 2019. Sienna also announced the appointment of Sean Andrews to the Company's leadership team as Vice President, Investor Relations (IR).

Mr. Andrews has served as Sienna's Senior Director, Investor Relations, since May 2017. Mr. Azoy has served as Sienna's Corporate Controller since December 2017. During that time, he has worked directly with the Company's CFO on financing projects and preparing Sienna to be a public reporting company.

Mr. Azoy was previously the Vice President of Accounting for Smart & Final, a public consumer products retailer with over $4 billion in annual revenues and 12,000 employees, from January 2016 to November 2017. In this role, he oversaw accounting operations, Sarbanes-Oxley compliance and Securities and Exchange Commission (SEC) financial reporting. Mr. Azoy was the Corporate Controller for Kythera Biopharmaceuticals from March 2015 until December 2015, after it was acquired by Allergan plc.

At Kythera, he had responsibility for accounting and tax functions, as well as SEC financial reporting and preparing the company for its first commercial product launch. From June 2013 to March 2015, Mr. Azoy served as Director, Finance Business Strategy for Warner Bros. Entertainment, supporting corporate finance initiatives and mergers and acquisitions.

From 2003 to 2013, he held roles of increasing responsibility in Ernst & Young's audit practice, serving clients in the life sciences sector, including Amgen.